Unum Therapeutics, a biotech out of Cambridge, Massachusetts which is developing a universal cellular immunotherapy to treat multiple cancers, has hired Geoffrey Hodge as Senior Vice President, Operations, effective immediately. Mr. Hodge will be responsible for leading both technical operations, including process development and manufacturing of the company’s proprietary antibody-coupled T-cell receptor (ACTR) therapies, and non-technical operations at Unum.
MIGDAL HA’EMEQ, Israel, Enzymotec Ltd. (Nasdaq:ENZY) , a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the appointment of Tamar Howson to its Board of Directors, effective July 29, 2015.
Complix, a biopharmaceutical company focused on developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases, today announced the appointment of Hans Schikan as Chairman of its Board of Directors.
A new UK company focused on acquiring, rapidly developing and commercialising innovative medicines to transform patient quality of life and improve human health
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that Dr. Jessica Hopfield has been appointed to Insulet’s Board of Directors.
Denali Therapeutics, a San Francisco based biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that Carole Ho, M.D., has joined the company as Chief Medical Officer and Head of Development. In this role, Dr. Ho will lead the translational and clinical development activities at Denali and serve on the Executive Leadership Team.
Aegerion has faced increasing investor pressure of late, with a barrage of hostilities from activist investor, Alex Denner. He won a breakthrough earlier this year when a standstill agreement was reached with the board and CEO, Marc Beer, to nominate an independent board director for his investment firm Sarissa Capital Management, installing Jorge Plutzky as the nominated independent director . Denner is a former investor with Carl Icahn, also famed for his aggressive investor activism and ability to use corporate governance to enforce change.
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). Alongside the existing investors, Novo A/S and SV Life Sciences, the round included additional international healthcare investors experienced in plasma kallikrein targeted mechanisms led by RA Capital Management and including Longwood Fund and Venrock.
Fresh from announcing that Hans Schikan, ex-CEO of Prosensa, would be joining the Board of Directors at Wilson Therapeutics, the company have announced the appointment of another Genzyme allumni, Dr. Carl Bjartmar as chief medical officer (CMO). Dr. Bjartmar will report to Jonas Hansson, chief executive officer, and will join the company’s management team.